Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of ...

Piramal's global Contract Development and Manufacturing Organization plans to more than double the facility’s capacity by Q1 ...

Piramal Pharma Solutions Inc. today announced plans to expand its current Lexington operations with a nearly $80 million ...

Piramal Pharma Solutions, is investing $80 million to expand its Lexington facility, doubling capacity by Q1 2027 to meet ...

The expansion will equip the Lexington site with an additional 24,000 square feet of manufacturing space, a new lab, and ...

The investment has been financed through bank loans and internal accruals, and aims to enhance site’s capacity to meet rising ...

As the efficiency and efficacy of injectable treatment options improve, more patients are expected to benefit from advanced therapies.

Piramal Pharma’s stock price rose 2% in the opening trading on September 30 after the business received an Establishment ...

Piramal Pharma Solutions invests $80 million in Lexington facility expansion to meet growing demand in injectables market.

In July 2024, the USFDA inspected the said facility with Zero Form - 483 observations and No Action Indicated (NAI) ...

Piramal Pharma Solutions (PPS), a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma has unveiled an $80M investment plan to expand its Lexington, ...

Piramal Pharma aims to achieve $2 billion in annual revenue with a 25% operating margin by fiscal 2030, driven by its CDMO ...